Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 359

COVID Susceptibility Index can help to manage outbreaks

Background: At a recent UNSW virtual research seminar, Calise Liu and Alan Xian presented their research on developing a COVID-19 Susceptibility Index. This interview explores the research and its potential applications. Calise works at Finity Consulting, which specialises in actuarial and strategic analytics consulting. Alan has nearly finished his PhD at UNSW and will start a role at Macquarie University later this year. 

David: With your actuarial backgrounds, what motivated you to get involved in COVID-19 research, which to many is the domain of medical researchers?

Calise: Once you have data (and there is a lot of data available), many of the skills required to analyse that data are universal. We had read a lot of medical literature but hadn’t seen the translation of those results to the Australian population. Actuaries are particularly well-placed because we have expertise in modelling large demographic data sets. Of course, we are not medical experts and so we made sure to get specialist medical input. We held discussions with six medical experts on the design aspects of our research.

David: Why the focus on susceptibility?

Alan: There was already a lot of research modelling transmission of the virus. We noticed a research gap in terms of investigating susceptibility at a demographic level. Susceptibility, the risk of severe illness or death if an individual were to contract the virus, is important in many ways. At a government level, susceptibility tells you how bad it could be in each region if an outbreak were to occur. This then informs decisions around resource allocation and how quickly you want to be able to identify and treat known cases.

David: Explain how you have developed the Susceptibility Index.

Alan: We combined age characteristics (60-69, 70-79, and 80+) with five health aspects (known as co-morbidities): cardiovascular disease, respiratory disease, cancer, diabetes and obesity. Unfortunately, the data shows that certain groups – notably the elderly with multiple health issues – are many times more likely to have severe reactions if infected with COVID-19, compared with young healthy people.

Calise: By combining our susceptibility score with Finity’s Defin’d dataset of socio-demographic and geographic attributes, we can explore COVID-19 impacts by area, household composition, income band, industry and more. We found some evidence of vulnerable populations away from capital cities, where multiple risk factors are more concentrated. We used heatmaps to visualise the susceptibility risk (red indicates areas with, on average, highest susceptibility).

The news is both good and bad. So far, most of the cases have occurred in areas with relatively-lower susceptibility. However, this is something to consider when looking at when, where and how to relax restrictions.

David: When you combine the demographic data with age and health factors, do any socio-economic effects emerge?

Alan: Unfortunately, we find that at-risk communities commonly have low socio-economic characteristics (i.e. low income). This isn’t surprising – when we spoke to our medical experts, they were aware that health issues and co-morbidities tend to present more strongly in poorer socio-economic groups. As a result, the disadvantaged segments of Australia may require additional resources as we start relaxing isolation measures.

David: What are the implications for government policy?

Calise: We think our work can inform policy in a number of ways. Our model provides an exposure measure for the Australian population that can serve as a foundation for various extensions. Transmission information can be overlaid to assess the impact of various policies. Our analysis can also highlight areas where outbreaks of COVID-19 may be particularly devastating, guiding decisions around allocation of financial and medical resources. Conversely, the additional economic information could be incorporated to examine trade-offs between simulating economic recovery and minimising risk to public safety.

David: I know this is early days, but have you been able to share this research with authorities?

Alan: We have had some interest from the Department of Health. We are happy to work with any interested parties to see how our work could be of assistance.

David: Finally, Alan, you’ve effectively put your PhD on hold, and Calise, you’ve been supported by Finity, but most of this research is outside of work hours. Do you think that this may be a feature of your future careers, jumping into projects outside your core line of research where you see the opportunity to contribute?

Calise: I think many young people view contribution as an important part of their career. I’m fortunate to have an analytical skillset which can be applied to different problems. 

Alan: I do have to finish my PhD soon and am looking forward to that light at the end of the tunnel. Luckily, I have supportive supervisors who share my view that these contributions are worthwhile pursuits. At the start of my PhD, what I really wanted was to produce societally beneficial research and so these projects are very exciting. 

 

Individuals with co-morbidities or symptoms associated with COVID-19 should follow the government advice and take extra precautions which can be found here.

If you would like to know more about the Susceptibility Index you can read more here.

 

David Bell is Executive Director of The Conexus Institute, a not-for-profit research institution focused on improving retirement outcomes for Australians. Calise Liu is a Fellow of the Institute of Actuaries of Australia and an intern at Finity Consulting. Alan Xian is a PhD candidate at UNSW.

 


 

Leave a Comment:

     

RELATED ARTICLES

What should the next generation's Australia look like?

Halving super drawdowns helps wealthy retirees most

Baby bust: will infertility shape Australia's future?

banner

Most viewed in recent weeks

10 little-known pension traps prove the value of advice

Most people entering retirement do not see a financial adviser, mainly due to cost. It's a major problem because there are small mistakes a retiree can make which are expensive and avoidable if a few tips were known.

Check eligibility for the Commonwealth Seniors Health Card

Eligibility for the Commonwealth Seniors Health Card has no asset test and a relatively high income test. It's worth checking eligibility and the benefits of qualifying to save on the cost of medications.

Hamish Douglass on why the movie hasn’t ended yet

The focus is on Magellan for its investment performance and departure of the CEO, but Douglass says the pandemic, inflation, rising rates and Middle East tensions have not played out. Vindication is always long term.

Start the year right with the 2022 Retiree Checklist

This is our annual checklist of what retirees need to be aware of in 2022. It is a long list of 25 items and not everything will apply to your situation. Run your eye over the benefits and entitlements.

At 98-years-old, Charlie Munger still delivers the one-liners

The Warren Buffett/Charlie Munger partnership is the stuff of legends, but even Charlie admits it is coming to an end ("I'm nearly dead"). He is one of the few people in investing prepared to say what he thinks.

Should I pay off the mortgage or top up my superannuation?

Depending on personal circumstances, it may be time to rethink the bias to paying down housing debt over wealth accumulation in super. Do the sums and ask these four questions to plan for your future.

Latest Updates

Investment strategies

Three ways index investing masks extra risk

There are thousands of different indexes, and they are not all diversified and broadly-based. Watch for concentration risk in sectors and companies, and know the underlying assets in case liquidity is needed.

Investment strategies

Will 2022 be the year for quality companies?

It is easy to feel like an investing genius over the last 10 years, with most asset classes making wonderful gains. But if there's a setback, companies like Reece, ARB, Cochlear, REA Group and CSL will recover best.

Shares

2022 outlook: buy a raincoat but don't put it on yet

In the 11th year of a bull market, near the end of the cycle, some type of correction is likely. Underneath is solid, healthy and underpinned by strong earnings growth, but there's less room for mistakes.

Gold

Time to give up on gold?

In 2021, the gold price failed to sustain its strong rise since 2018, although it recovered after early losses. But where does gold sit in a world of inflation, rising rates and a competitor like Bitcoin?

Investment strategies

Global leaders reveal surprises of 2021, challenges for 2022

In a sentence or two, global experts across many fields are asked to summarise the biggest surprise of 2021, and enduring challenges into 2022. It's a short and sweet view of the changes we are all facing.

Shares

What were the big stockmarket listings in record 2021?

In 2021, sharemarket gains supported record levels of capital raisings and IPOs in Australia. The range of deals listed here shows the maturity of the local market in providing equity capital.

Economy

Let 'er rip: how high can debt-to-GDP ratios soar?

Governments and investors have been complacent about the build up of debt, but at some level, a ceiling exists. Are we near yet? Trouble is brewing, especially in the eurozone and emerging countries.

Sponsors

Alliances

© 2022 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.

Website Development by Master Publisher.